107 related articles for article (PubMed ID: 20153243)
1. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
Lee HW; Hwang YH; Han JH; Choi JH; Kang SY; Jeong SH; Ann MS; Oh YT; Kim JH; Kim CH; Sheen SS
Oral Oncol; 2010 Mar; 46(3):209-13. PubMed ID: 20153243
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
[TBL] [Abstract][Full Text] [Related]
4. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Huang PY; Li Y; Mai HQ; Luo RZ; Cai YC; Zhang L
Oral Oncol; 2012 Oct; 48(10):964-968. PubMed ID: 22571922
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
6. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
[TBL] [Abstract][Full Text] [Related]
7. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
Jeong SH; Jung JH; Han JH; Kim JH; Choi YW; Lee HW; Kang SY; Hwang YH; Ahn MS; Choi JH; Oh YT; Chun M; Kang S; Park KJ; Hwang SC; Sheen SS
Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
[TBL] [Abstract][Full Text] [Related]
8. Correlation between ERCC1 expression and concurrent chemotherapy and radiotherapy in patients with locally advanced nasopharyngeal cancer.
Liang R; Lin Y; Liu ZH; Liao XL; Yuan CL; Liao SN; Li YQ
Genet Mol Res; 2015 May; 14(2):5804-11. PubMed ID: 26125779
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
Kim MK; Cho KJ; Kwon GY; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Kim SB
Eur J Cancer; 2008 Jan; 44(1):54-60. PubMed ID: 17976974
[TBL] [Abstract][Full Text] [Related]
10. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
11. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
Lee HW; Han JH; Kim JH; Lee MH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS; Lim HY
Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
[TBL] [Abstract][Full Text] [Related]
12. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.
Sun JM; Ahn MJ; Park MJ; Lee HY; Ahn JS; Lee S; Kang G; Han J; Son YI; Baek CH; Ahn YC; Park K
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):655-60. PubMed ID: 21621119
[TBL] [Abstract][Full Text] [Related]
13. Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy.
Zhang Z; Jiang C; Hu L
Tumori; 2014; 100(3):328-32. PubMed ID: 25076246
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
Kim KH; Kwon HC; Oh SY; Kim SH; Lee S; Kwon KA; Jang JS; Kim MC; Kim SJ; Kim HJ
Biomarkers; 2011 Feb; 16(1):74-82. PubMed ID: 21133646
[TBL] [Abstract][Full Text] [Related]
16. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
17. Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?
Chan SH; Cheung FM; Ng WT; Choi CW; Cheung KN; Yiu KH; Lee AW
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1414-20. PubMed ID: 20605357
[TBL] [Abstract][Full Text] [Related]
18. Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
Kao SC; Lee K; Klebe S; Henderson D; McCaughan B; Vardy J; Clarke S; van Zandwijk N
Clin Lung Cancer; 2013 Mar; 14(2):164-71. PubMed ID: 23085037
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of histological typing in nasopharyngeal carcinoma.
Cheung F; Chan O; Ng WT; Chan L; Lee A; Pang SW
Oral Oncol; 2012 May; 48(5):429-33. PubMed ID: 22177891
[TBL] [Abstract][Full Text] [Related]
20. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Shen C; Chen L; Fu J; Lin H
J Cancer Res Ther; 2016 Oct; 12(Supplement):72-75. PubMed ID: 27721259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]